The Motley Fool Previous Page

Dilution Lurks at AOB

Brian Lawler
August 13, 2008

On Monday, Motley Fool Hidden Gems pick American Oriental Bioengineering (Nasdaq: AOB  ) released some stellar year-over-year growth numbers. But investors should be wary of the growing share count fueling that performance.

In the second quarter, AOB posted a 74% revenue increase and a 43% jump in net income versus last year. While nearly any company would celebrate these sort of top and bottom-line growth rates, it's important to keep in mind that AOB primarily grows its health-care-supplements business through acquisitions -- specifically, acquisitions funded by dilutive equity financings.

If a company is furiously selling new shares to buy its growth, even a 100% increase in net income from one period to the next can leave shareholders with a smaller piece of the earnings pie. That's partly why you see AOB's earnings per share increasing more slowly than its revenue and net income's torrid pace:


Net Income

Net Income Growth (YOY)

Earnings per share

EPS Growth (YOY)

Q2 2008

$13.9 million




Q1 2008

$9.4 million




Q4 2007

$15.3 million